U.S. Pharma Stock News

Immunome earnings and shelf registration set the stage Immunome (IMNM) has drawn fresh attention after reporting a full year 2025 net loss of US$212.39 million, which was narrower than the prior year, alongside a new shelf registration for up to roughly US$156 million in common stock. See our latest analysis for Immunome. Against this backdrop, Immunome’s share price has been choppy, with a 7.68% 90 day share price return and a 12.14% 30 day share price decline. Yet longer term momentum...

Why Constellium is on investors’ radar today Constellium (NYSE:CSTM) is drawing attention after a strong past 3 months, with the stock showing a 40.5% total return and a 115.3% total return over the past year. For investors tracking industrial materials, that recent performance is prompting a closer look at how Constellium’s $8,449.0 million in revenue and $273.0 million in net income line up with its current share price of $25.49. See our latest analysis for Constellium. At a share price of...

Voyager Technologies (VOYG) just closed FY 2025 with Q4 revenue of US$46.7 million and a basic EPS loss of US$0.52. Trailing 12 month revenue came in at US$166.4 million against a full year EPS loss of US$2.89 and revenue growth of 15.4% over the past year. The company has seen quarterly revenue range from US$34.5 million to US$46.7 million this year, with basic EPS losses stretching from US$0.28 to US$3.45 per quarter. Trailing 12 month net income excluding extra items was a loss of US$116.1...

O-I Glass (OI) recently flagged tougher than expected trading in early 2026, citing softer European demand, temporary supply chain costs from factory closures, and pricing pressure in wine, while still keeping its full year guidance intact. See our latest analysis for O-I Glass. Those softer early 2026 trading conditions and European headwinds help explain why the 30 day share price return sits at a 29.89% decline and the year to date share price return is down 23.09%. At the same time, the 1...

Why Biohaven is back on traders' screens Biohaven (BHVN) is back in focus after upbeat analyst commentary on its epilepsy drug opakalim, stronger sentiment following a peer’s Phase 3 epilepsy result, and a sector wide reaction to US regulatory leadership changes. See our latest analysis for Biohaven. Despite a positive 1 day share price return of 0.59% to US$10.27 after the recent analyst commentary and sector tailwinds, Biohaven’s 30 day share price return of 11.47% and 1 year total...

John Wiley & Sons (WLY) is back in focus after reporting fiscal third quarter earnings that returned the business to profitability, alongside steady revenue, expanding AI driven research offerings, and active share repurchases. See our latest analysis for John Wiley & Sons. The recent Q3 profit rebound and ongoing buybacks appear to have shifted sentiment, with a 25.21% 1 month share price return and a 24.10% year to date share price return, even though the 1 year total shareholder return is...

If you are wondering whether Universal Health Services is offering fair value at around US$186.53, you are not alone. This article focuses on what the numbers say about the stock today. The share price has pulled back recently, with an 8.9% decline over the last 7 days and a 14.7% decline over the last 30 days. However, the 1 year and 3 year returns of 8.5% and 62.2% respectively still stand out. Recent news around Universal Health Services has focused on the company as a key player in the...

Edison International (NYSE:EIX) secured a dismissal of a shareholder lawsuit challenging its wildfire risk disclosures. The case focused on statements made before the January 2025 Los Angeles wildfires. The ruling removes a specific litigation claim tied to how the company communicated wildfire exposure to investors. Edison International, the parent of Southern California Edison, sits at the center of ongoing debates around utility wildfire exposure and risk management in California. The...

Altria Group (MO) is back on investors’ radar after recent share price moves, with the stock last closing at $67.14. You might be weighing how its returns and fundamentals currently line up. See our latest analysis for Altria Group. The latest move to $67.14 comes after a 14.4% 90 day share price return and a 17.15% year to date share price return, with a 1 year total shareholder return of 23.74% indicating solid momentum over a longer horizon. If this has you thinking about where else...

Event context and recent performance Northwest Natural Holding (NWN) has drawn investor attention after recent trading, with the stock closing at US$51.62 and showing mixed short term moves, including a 1 day decline and a gain over the past month. See our latest analysis for Northwest Natural Holding. That 1 day share price pullback sits against a firmer backdrop, with a 30 day share price return of 7.39%, year to date gain of 10.44%, and a 1 year total shareholder return of 30.13%,...

EchoStar (SATS) is in the spotlight after selling US$42.65b of spectrum to AT&T and SpaceX. The company is cutting net debt and bankruptcy risk, while preparing the EchoStar XXV launch and reshaping its Pay TV and Broadband operations. See our latest analysis for EchoStar. The share price is at US$108.50 after a 7 day share price return of a 7.19% decline and a 90 day share price return of a 4.35% gain. The 1 year total shareholder return of just over 3x suggests powerful longer term...

Wondering whether Albemarle's current share price gives you a fair deal, or if the market is mispricing the stock? This article focuses on what the numbers say about value rather than the hype. Albemarle's share price last closed at US$166.54, with returns of 1.1% over 7 days, 1.9% over 30 days, 15.7% year to date, 133.9% over 1 year, negative 22.7% over 3 years and 13.4% over 5 years. Taken together, these figures give you a mixed picture of recent and longer term performance. Recent...

If you are wondering whether Dollar General's share price around its recent US$146 close still offers value, you are not alone. This article is built to help you weigh what that price might actually represent. The stock has had a mixed run, with a 4.6% decline over the last 7 days, a 0.4% decline over 30 days, but a 6.7% gain year to date and an 89.7% return over the past year, set against 3-year and 5-year returns of 28.0% and 18.4% declines respectively. Recent coverage of Dollar General...

In recent days, Hecla Mining reported that its fortunes have swung with precious metal prices, as weaker gold but stronger silver prices, alongside a firmer US dollar and rising interest rates, pulled its operations and investor sentiment in different directions. At the same time, management has intensified the company’s focus on silver by selling gold assets and boosting silver exploration and pre-development activity, tying Hecla’s outlook even more closely to conditions in the silver...

Fastly has appointed KPMG as its new independent registered public accounting firm, replacing Deloitte & Touche LLP. The change in auditor represents a shift in the company’s oversight of financial reporting and internal controls. For investors tracking NasdaqGS:FSLY, this auditor switch comes at a time when the stock price is $22.74 and recent returns have been very strong. The shares show a 7.6% return over the past week, 165.3% over the past month, 123.2% year to date, and 245.6% over...

If you are wondering whether Flowserve's current share price still offers value after a strong run, you are not alone. This article will walk through how the market might be pricing the stock today. Flowserve shares last closed at US$78.71, with returns of 68.7% over 1 year and 11.3% year to date, even though the stock has seen a 5.7% decline over 7 days and a 7.9% decline over 30 days. Recent coverage around Flowserve has focused on the business as an established player in the capital goods...

Quest Diagnostics (NYSE:DGX) has partnered with Guardant Health to offer the FDA approved Shield blood test for colorectal cancer screening. The agreement will make Shield available nationwide through Quest’s testing ecosystem, expanding access for patients and clinicians. The collaboration focuses on a blood based option for colorectal cancer screening that may support broader adoption of preventive care. For you as an investor, this move plugs directly into what Quest Diagnostics already...

If you are wondering whether ServiceNow's current share price lines up with its underlying worth, you are not alone. This article is going to focus squarely on that question. The stock last closed at US$116.61, with returns of 3.0% over 7 days and 15.8% over 30 days. This is set against a year to date return of a 20.9% decline and a 1 year return of a 27.9% decline, while the 3 year and 5 year returns sit at 37.3% and 16.8% respectively. Recent news coverage around ServiceNow has focused on...

If you are wondering whether EPAM Systems is starting to look like value after a tough run, this breakdown will help you frame the price you see against what you are actually getting. The stock last closed at US$142.18, with a 1% gain over the past week but declines of 23.8% over 30 days, 29.1% year to date and 25.7% over the past year, extending a 50.2% 3 year and 61.7% 5 year slide. Recent coverage around EPAM Systems has largely focused on its position within the software and IT services...

Gilead Sciences (NasdaqGS:GILD) plans to acquire Arcellx in a deal valued at up to $7.8b. The transaction is aimed at expanding Gilead's cancer cell therapy pipeline, especially in multiple myeloma. The deal is expected to close in the second quarter of 2026, subject to customary approvals. Gilead Sciences, trading at $148.56, has seen a 22.2% return year to date and a 33.5% return over the past year. Over longer periods, the stock has recorded a 105.0% return over three years and 178.0%...

If you are wondering whether Sonos at US$14.23 is an opportunity or a value trap, you are in the right place for a clear look at what the current price actually reflects. The stock has had a mixed ride, with a 16.7% decline over the past month and an 18.6% decline year to date, yet it is still up 21.5% over the last year after a much weaker 3 and 5 year return picture. Recent attention on Sonos has focused on its position in consumer audio hardware, including interest in how its product...

What Sandisk’s Recent Performance Tells You With no single headline event driving attention, Sandisk (SNDK) has still drawn interest after a 5.1% move in the past day and a very large total return over the past 3 months. See our latest analysis for Sandisk. That 5.1% 1 day share price return at a last close of $618.89 comes on top of a 9.5% 7 day and 3.5% 30 day share price return. The roughly 17x 1 year total shareholder return implies investors have rapidly reassessed Sandisk’s prospects...

Southern Copper (SCCO) is back in focus after a 3.60% share price drop, which has been linked to weaker copper prices, cautious economic signals from China, analyst downgrades, and insider selling following strong quarterly earnings. See our latest analysis for Southern Copper. Zooming out, Southern Copper’s recent weakness, with a 7 day share price return of negative 4.88% and 30 day share price return of negative 1.11%, sits against a much stronger backdrop. This includes a 90 day share...

Royal Gold (RGLD) has come back into focus after its appearance at the 47th Annual Raymond James Institutional Investor Conference, where management highlighted operational efficiency, dividend consistency, and future growth projects including Platreef, MARA, and Four Mile. See our latest analysis for Royal Gold. Royal Gold’s recent conference appearance and dividend affirmation come against a backdrop of stronger price action, with a 30 day share price return of 5.99%, a 90 day share price...